Skip to content
HowShorted

Zynerba Pharmaceuticals, Inc. short interest in 2018

In 2018, Zynerba Pharmaceuticals, Inc.'s disclosed short interest ran from 16.53% of shares outstanding on 12 Jan 2018 to 12.06% on 31 Dec 2018, a change of -4.47 percentage points. The year's high was 20.19% on 30 Apr 2018 and its low 9.64% on 15 Aug 2018, averaging 15.53% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.50 days on 31 May 2018. Full history: Zynerba Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for Zynerba Pharmaceuticals, Inc. in 2018

2018 in figures

Start of year
16.53% (12 Jan 2018)
End of year
12.06% (31 Dec 2018)
Change
-4.47 pp
High
20.19% (30 Apr 2018)
Low
9.64% (15 Aug 2018)
Average
15.53%
Highest days to cover
12.50 (31 May 2018)
SEC filings marked
9

Every report in 2018

Zynerba Pharmaceuticals, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201816.53%6.54
31 Jan 201816.74%6.85
15 Feb 201817.64%11.04
28 Feb 201815.91%11.43
15 Mar 201819.40%6.1210-K filed, results (8-K)
29 Mar 201819.23%10.45
13 Apr 201819.77%9.87
30 Apr 201820.19%10.67
15 May 201819.03%10.6210-Q filed, results (8-K)
31 May 201818.99%12.50
15 Jun 201818.27%12.37
29 Jun 201817.08%4.73
13 Jul 201817.06%8.05
31 Jul 201811.97%2.63results (8-K)
15 Aug 20189.64%3.1210-Q filed, results (8-K)
31 Aug 201810.11%2.14
14 Sep 201811.35%5.92
28 Sep 201814.60%3.15
15 Oct 201814.60%7.57
31 Oct 201814.46%6.56
15 Nov 201813.90%8.7410-Q filed, results (8-K)
30 Nov 201813.33%8.52
14 Dec 201810.91%9.93
31 Dec 201812.06%5.40

See also: Zynerba Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.